1
|
Molodecky NA, Soon IS, Rabi DM, Ghali WA,
Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema
HW and Kaplan GG: Increasing incidence and prevalence of the
inflammatory bowel diseases with time, based on systematic review.
Gastroenterol. 142:46–54. 2012.PubMed/NCBI View Article : Google Scholar
|
2
|
Jess T, LoftusEV Jr, Velayos FS, Harmsen
WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ 3rd, Munkholm
P and Sandborn WJ: Incidence and prognosis of colorectal dysplasia
in inflammatory bowel disease: A population-based study from
olmsted county, Minnesota. Inflamm Bowel Dis. 12:669–676.
2006.PubMed/NCBI View Article : Google Scholar
|
3
|
Chen R, Lai LA, Brentnall TA and Pan S:
Biomarker for colitis-associated colorectal cancer. World J
Gastroenterol. 22:7882–7891. 2016.PubMed/NCBI View Article : Google Scholar
|
4
|
Watanabe T, Konishi T, Kishimoto J, Kotake
K, Muto T and Sugihara K: Japanese Society for Cancer of the Colon
and Rectum. Ulcerative colitis-associated colorectal cancer shows a
poorer survival than sporadic cancer: A nationwide Japanese study.
Inflamm Bowel Dis. 17:802–808. 2011.PubMed/NCBI View Article : Google Scholar
|
5
|
DeRoche TC, Xiao SY and Liu X:
Histological evaluation in ulcerative colitis. Gastroenterol Rep
(Oxf). 2:178–192. 2014.PubMed/NCBI View Article : Google Scholar
|
6
|
Okamoto R and Watanabe M: Role of
epithelial cells in the pathogenesis and treatment of inflammatory
bowel disease. J Gastroenterol. 51:11–21. 2016.PubMed/NCBI View Article : Google Scholar
|
7
|
Triantafillidis JK, Nasioulas G and
Kosmidis PA: Colorectal cancer and inflammatory bowel disease:
Epidemiology, risk factors, mechanisms of development and
prevention strategies. Anticancer Res. 29:2727–2737.
2009.PubMed/NCBI
|
8
|
Vogelstein B, Fearson ER, Hamilton SR,
Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM
and Bos JL: Genetic alterations during colorectal-tumor
development. N Engl J Med. 319:525–532. 1988.PubMed/NCBI View Article : Google Scholar
|
9
|
Ullmam TA and Itzkowitz SH: Intestinal
inflammation and cancer. Gastroenterology. 140:1807–1816.
2011.PubMed/NCBI View Article : Google Scholar
|
10
|
Takahashi H, Ishikawa T, Ishiguro M,
Okazaki S, Mogushi K, Kobayashi H, Iida S, Mizushima H, Tanaka H,
Uetake H and Sugihara K: Prognostic significance of Traf2- and Nck-
interacting kinase (TNIK) in colorectal cancer. BMC Cancer.
15(794)2015.PubMed/NCBI View Article : Google Scholar
|
11
|
Hanaoka M, Ishikawa T, Ishiguro M, Tokura
M, Yamauchi S, Kikuchi A, Uetake H, Yasuno M and Kawano T:
Expression of ATF6 as a marker of pre-cancerous atypical change in
ulcerative colitis-associated colorectal cancer. A potential role
in the management of dysplasia. J Gastroenterol. 53:631–641.
2018.PubMed/NCBI View Article : Google Scholar
|
12
|
Sakthianandeswaren A, Christie M,
D'Andreti C, Tsui C, Jorissen RN, Li S, Fleming NI, Gibbs P, Lipton
L, Malaterre J, et al: PHLDA1 expression marks the putative
epithelial stem cells and contributes to intestinal tumorigenesis.
Cancer Res. 71:3709–3719. 2011.PubMed/NCBI View Article : Google Scholar
|
13
|
Khamas A, Ishikawa T, Shimokawa K, Mogushi
K, Iida S, Ishiguro M, Mizushima H, Tanaka H, Uetake H and Sugihara
K: Screening for epigenetically masked genes in colorectal cancer
using 5-Aza-2'-deoxycytidine, microarray and gene expression
profile. Cancer Genomics Proteomics. 9:67–75. 2012.PubMed/NCBI
|
14
|
Krajewska M, Krajewski S, Epstein JI,
Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC:
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1
expression in prostate cancers. Am J Pathol. 148:1567–1576.
1996.PubMed/NCBI
|
15
|
Shigaki K, Mitomi H, Fujimori T, Ichikawa
K, Tomita S, Imura J, Fujii S, Itabashi M, Kameoka S, Sahara R and
Takenoshita S: Immunohistochemical analysis of chromogranin A and
p53 expressions in ulcerative colitis-associated neoplasia:
Neuroendocrine differentiation as an early event in the
colitis-neoplasia sequence. Hum Pathol. 44:2393–2399.
2013.PubMed/NCBI View Article : Google Scholar
|
16
|
Lemmon MA and Ferguson KM:
Signal-dependent membrane targeting by pleckstrin homology (PH)
domains. Biochem J. 15:1–18. 2000.PubMed/NCBI
|
17
|
Scheffzek K and Welti S: Pleckstrin
homology (PH) like domains - versatile modules in protein-protein
interaction platforms. FEBS Lett. 586:2662–2673. 2012.PubMed/NCBI View Article : Google Scholar
|
18
|
Hinz T, Flindt S, Marx A, Janssen O and
Kabelitz D: Inhibition of protein synthesis by the T cell
receptor-inducible human TDAG51 gene product. Cell Signal.
13:345–352. 2001.PubMed/NCBI View Article : Google Scholar
|
19
|
Neef R, Kuske MA, Pröls E and Johnson JP:
Identification of the human PHLDA1/TDAG51 gene: Down-regulation in
metastatic melanoma contributes to apoptosis resistance and growth
deregulation. Cancer Res. 62:5920–5929. 2002.PubMed/NCBI
|
20
|
Nagai MA, Fregnani JH, Netto MM, Brentani
MM and Soares FA: Down-regulation of PHLDA1 gene expression is
associated with breast cancer progression. Breast Cancer Res Treat.
106:49–56. 2007.PubMed/NCBI View Article : Google Scholar
|
21
|
Zhao P, Lu Y and Liu L: Correlation of
decreased expression of PHLDA1 protein with malignant phenotype of
gastric adenocarcinoma. Int J Clin Exp Pathol. 8:5230–5235.
2015.PubMed/NCBI
|
22
|
Marchiori AC, Casolari DA and Nagai MA:
Transcriptional up-regulation of PHLDA1 by 17beta-estradiol in
MCF-7 breast cancer cells. Braz J Med Biol Res. 41:579–582.
2008.PubMed/NCBI View Article : Google Scholar
|
23
|
Toyoshima Y, Karas M, Yakar S, Dupont J,
Helman L and LeRoith D: TDAG51 mediates the effects of insulin-like
growth factor I (IGF-I) on cell survival. J Biol Chem.
279:25898–25904. 2004.PubMed/NCBI View Article : Google Scholar
|
24
|
Hossain GS, van Thienen JV, Werstuck GH,
Zhou J, Sood SK, Dickhout JG, de Koning AB, Tang D, Wu D, Falk E,
et al: TDAG51 is induced by homocysteine, promotes
detachment-mediated programmed cell death, and contributes to the
cevelopment of atherosclerosis in hyperhomocysteinemia. J Biol
Chem. 278:30317–3027. 2003.PubMed/NCBI View Article : Google Scholar
|
25
|
Gomes I, Xiong W, Miki T and Rosner MR: A
proline- and glutamine-rich protein promotes apoptosis in neuronal
cells. J Neurochem. 73:612–622. 1999.PubMed/NCBI View Article : Google Scholar
|
26
|
Ren L, Mendoza A, Zhu J, Briggs JW, Halsey
C, Hong ES, Burkett SS, Morrow J, Lizardo MM, Osborne T, et al:
Characterization of the metastatic phenotype of a panel of
established osteosarcoma cells. Oncotarget. 6:29469–29481.
2015.PubMed/NCBI View Article : Google Scholar
|
27
|
Murata T, Sato T, Kamoda T, Moriyama H,
Kumazawa Y and Hanada N: Differential susceptibility to hydrogen
sulfide-induced apoptosis between PHLDA1-overexpressing oral cancer
cell lines and oral keratinocytes: Role of PHLDA1 as an apoptosis
suppressor. Exp Cell Res. 320:247–257. 2014.PubMed/NCBI View Article : Google Scholar
|
28
|
Coutinho-Camillo CM, Lourenço SV, Nonogaki
S, Vartanian JG, Nagai MA, Kowalski LP and Soares FA: Expression of
PAR-4 and PHLDA1 is prognostic for overall and disease-free
survival in oral squamous cell carcinomas. Virchows Arch.
463:31–39. 2013.PubMed/NCBI View Article : Google Scholar
|
29
|
Taylor HW, Boyle M, Smith SC, Bustin S and
Williams NS: Expression of p53 in colorectal cancer and dysplasia
complicating ulcerative colitis. Br J Surg. 80:442–444.
1993.PubMed/NCBI View Article : Google Scholar
|